DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $12.3333.

Several brokerages have commented on DMAC. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a research note on Friday, November 14th. They issued an “overweight” rating on the stock. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. TD Cowen assumed coverage on DiaMedica Therapeutics in a research report on Thursday, October 30th. They issued a “buy” rating on the stock. Finally, Wall Street Zen lowered DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th.

DiaMedica Therapeutics Price Performance

NASDAQ DMAC opened at $8.14 on Friday. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $10.42. The stock’s 50-day moving average is $8.36 and its two-hundred day moving average is $7.06. The firm has a market cap of $423.93 million, a P/E ratio of -11.46 and a beta of 1.11.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, equities analysts expect that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Insider Activity at DiaMedica Therapeutics

In other DiaMedica Therapeutics news, major shareholder Jan Stahlberg acquired 240,352 shares of DiaMedica Therapeutics stock in a transaction dated Wednesday, November 19th. The stock was bought at an average cost of $7.21 per share, with a total value of $1,732,937.92. Following the completion of the transaction, the insider owned 8,375,092 shares of the company’s stock, valued at $60,384,413.32. The trade was a 2.95% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased 1,061,277 shares of company stock worth $7,632,627 in the last three months. 7.30% of the stock is owned by insiders.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds have recently bought and sold shares of DMAC. Strs Ohio increased its holdings in shares of DiaMedica Therapeutics by 19.7% during the 3rd quarter. Strs Ohio now owns 9,100 shares of the company’s stock worth $63,000 after purchasing an additional 1,500 shares during the period. World Investment Advisors raised its holdings in DiaMedica Therapeutics by 7.3% in the 3rd quarter. World Investment Advisors now owns 34,325 shares of the company’s stock valued at $236,000 after acquiring an additional 2,350 shares in the last quarter. Rhumbline Advisers lifted its position in shares of DiaMedica Therapeutics by 14.5% in the 3rd quarter. Rhumbline Advisers now owns 27,357 shares of the company’s stock worth $188,000 after acquiring an additional 3,463 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth approximately $29,000. Finally, BNP Paribas Financial Markets increased its position in shares of DiaMedica Therapeutics by 24.4% during the second quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock valued at $74,000 after purchasing an additional 3,709 shares during the period. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.